Assorted News from the Last Week: Childhood cancer cases are on the rise across the EU. Zebrafish models offer fast, effective guidance for personalized therapies
Assorted News from the Last Week: NCI explains the transition of pediatric brain tumor trials to the PEP-CTN. Up to 10% of pediatric hematologic malignancies
Assorted News from the Last Week: September is Childhood Cancer Awareness Month. Read CAC2 staffer Bethany Lieberman’s observations of how the Childhood Cancer Hub team
Assorted News from the Last Week: Bad news to start Childhood Cancer Awareness Month: The Pediatric Brain Tumor Consortium, a network dedicated to early phase
Assorted News from the Last Week: Bad news to start Childhood Cancer Awareness Month: The Pediatric Brain Tumor Consortium, a network dedicated to early phase
Assorted News from the Last Week: How wearable devices are empowering childhood cancer survivors. Improving fever management of hospitalized children with cancer: Barriers, facilitators, and
Assorted News from the Last Week: CAC2 Student Member and Rookie-of-the Year Joshua Omale published on the global rise in young-onset cancers and the role
Assorted News from the Last Week: CAC2 Supporting Organization Jazz Pharmaceuticals announced that the FDA granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of
Assorted News from the Last Week: Scoping review of the utilization of wearable devices in pediatric and young adult oncology Engineered L-asparaginase variants with enhanced
Assorted News from the Last Week: Researchers at the University of Florida are moving closer to developing what they have described as a “universal” cancer
